Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Marc Jacquemin"'
Autor:
Caroline P. Martens, Pierre Van Mol, Joost Wauters, Els Wauters, Tanja Gangnus, Bernard Noppen, Hanne Callewaert, Jean H.M. Feyen, Laurens Liesenborghs, Elisabeth Heylen, Sander Jansen, Leydi Carolina Velásquez Pereira, Sirima Kraisin, Ipek Guler, Matthias M. Engelen, Anna Ockerman, Anke Van Herck, Robin Vos, Christophe Vandenbriele, Philippe Meersseman, Greet Hermans, Alexander Wilmer, Kimberly Martinod, Bjoern B. Burckhardt, Marc Vanhove, Marc Jacquemin, Peter Verhamme, Johan Neyts, Thomas Vanassche
Publikováno v:
EBioMedicine, Vol 83, Iss , Pp 104195- (2022)
Summary: Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to the angiotensin-converting enzyme 2 (ACE2) receptor, a critical component of the kallikrein-kinin system. Its dysregulation may lead to increased vascular perm
Externí odkaz:
https://doaj.org/article/e22bccf7e13b4f4e9d17aa33606b5009
Autor:
Suryasarathi Dasgupta, Ana Maria Navarrete, Sebastien André, Bharath Wootla, Sandrine Delignat, Yohann Repessé, Jagadeesh Bayry, Antonino Nicoletti, Evgueni L. Saenko, Roseline d’Oiron, Marc Jacquemin, Jean-Marie Saint-Remy, Srini V. Kaveri, Sebastien Lacroix-Desmazes
Publikováno v:
Haematologica, Vol 93, Iss 1 (2008)
Background The development of factor VIII (FVIII) inhibitors remains the major hurdle in the clinical management of patients with hemophilia A. FVIII uptake by professional antigen-presenting cells (APC) is the first step involved in initiation of im
Externí odkaz:
https://doaj.org/article/17d0f28f359c4df2b641a883bc33ad09
Autor:
Laleh Salarilak, Zahra Pirdel, Hossein Dinmohammadi, Hassan Rokni‐Zadeh, Renaud Lavend'homme, Mehran Karimi, Marc Jacquemin, Tina Shahani
Publikováno v:
Journal of Cellular and Molecular Medicine. 27:30-35
Autor:
Rozenn Quarck, Lynn Willems, Birger Tielemans, Leanda Stoian, Alicja Ronisz, Allard Wagenaar, Frédéric Perros, Guido Claessen, Agnieszka Ciarka, Laurent Godinas, Catharina Belge, Marc Jacquemin, Marion Delcroix
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology.
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening condition and rare complication of acute pulmonary embolism. Mechanisms underlying impaired clot resolution and in sustained fibrothrombotic obstruction of the pu
Autor:
Laleh, Salarilak, Zahra, Pirdel, Hossein, Dinmohammadi, Hassan, Rokni-Zadeh, Renaud, Lavend'homme, Mehran, Karimi, Marc, Jacquemin, Tina, Shahani
Publikováno v:
Journal of cellular and molecular medicineREFERENCES. 27(1)
The splenic endothelial Weibel-palade bodies are one of the most important candidate organelles to release von Willebrand factor upon stimulation with desmopressin. However, the presence of functional desmopressin-specific receptor has not yet been d
Autor:
Kathelijne Peerlinck, Silvia Lazzaro, Peter J. Friend, D Nasralla, Ina Jochmans, Jacques Pirenne, Marc Jacquemin, Diethard Monbaliu, Renaud Lavend'homme, Rutger J. Ploeg, Nicholas Gilbo, Louis Libbrecht
Publikováno v:
Transplantation, Vol. 106, no. 3, p. 510-518 (2022)
BACKGROUND: Coagulation factors may inform on liver function during normothermic machine perfusion (NMP). We investigated whether graft ischemic injury impairs the accumulation of anticoagulation factors during NMP of porcine and human livers. METHOD
Autor:
Chantal Thys, Kathleen Freson, Kathelijne Peerlinck, Marc Jacquemin, Christine Van Laer, Veerle Labarque, Kate Downes
Publikováno v:
Thrombosis and haemostasis. 122(6)
Autor:
Zuben E. Sauna, Basil Golding, Wojciech Jankowski, Marc Jacquemin, H.A. Daniel Lagassé, Louis B. Hopkins
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
The most challenging complication associated with Factor VIII (FVIII) replacement therapy is the development of neutralizing anti-drug antibodies, or inhibitors, which occur in 23-35% of severe (FVIII level via neonatal Fc receptor (FcRn) binding, ot
Autor:
Marc Jacquemin, Ines Van den bosch, Thomas Vanassche, Maarten Coemans, Thomas Bouillon, Björn Meijers, Dirk Kuypers, Peter Verhamme
Background Apixaban, a direct oral anticoagulant inhibiting factor Xa, has been proven to reduce the risk of atrial fibrillation-related stroke and thromboembolism in patients with mild to moderate renal insufficiency. Patients on renal replacement t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d49d81c1ddfcbfcc724fa2251138be2f
https://lirias.kuleuven.be/handle/20.500.12942/686191
https://lirias.kuleuven.be/handle/20.500.12942/686191
Autor:
Robin Vos, Griet Pieters, Stefan Janssens, Steffen Rex, Joost Wauters, Thomas Vanassche, Kathelijne Peerlinck, Pieter Sinonquel, Eveline Claeys, Natalie Lorent, Matthias M. Engelen, Tim Balthazar, Marc Jacquemin, Lorenz Van der Linden, Jan Gunst, Ipek Guler, Peter Verhamme, Christophe Vandenbriele, Laurens Liesenborghs, Christine Van Laer, Alexander Wilmer
Publikováno v:
Seminars in thrombosis and hemostasis. 47(4)
Background Venous thromboembolism (VTE) is a frequent complication of COVID-19, so that the importance of adequate in-hospital thromboprophylaxis in patients hospitalized with COVID-19 is well established. However, the incidence of VTE after discharg